Literature DB >> 23341180

Oral anticoagulants in older adults with atrial fibrillation.

Gwen M Bernacki1, Richard C Becker.   

Abstract

Atrial fibrillation (AF) is the most common arrhythmia in adults and contributes directly to adverse clinical events, ranging from ischemic stroke to heart failure and cardiovascular death. Because the incidence of AF and its attendant complications increase with age, there is a strong and growing need to develop safe, effective and widely available therapies. The following review summarizes the use of oral anticoagulants in older adults with AF, focusing on practical topics such as drug metabolism, drug-drug interactions, co-morbidities and cost considerations in a complex payer environment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23341180      PMCID: PMC7037576          DOI: 10.1007/s11239-013-0869-0

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  67 in total

1.  Rivaroxaban in patients with a recent acute coronary syndrome.

Authors:  Jessica L Mega; Eugene Braunwald; Stephen D Wiviott; Jean-Pierre Bassand; Deepak L Bhatt; Christoph Bode; Paul Burton; Marc Cohen; Nancy Cook-Bruns; Keith A A Fox; Shinya Goto; Sabina A Murphy; Alexei N Plotnikov; David Schneider; Xiang Sun; Freek W A Verheugt; C Michael Gibson
Journal:  N Engl J Med       Date:  2011-11-13       Impact factor: 91.245

2.  Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF.

Authors:  Graeme J Hankey; Manesh R Patel; Susanna R Stevens; Richard C Becker; Günter Breithardt; Antonio Carolei; Hans-Christoph Diener; Geoffrey A Donnan; Jonathan L Halperin; Kenneth W Mahaffey; Jean-Louis Mas; Ayrton Massaro; Bo Norrving; Christopher C Nessel; John F Paolini; Risto O Roine; Daniel E Singer; Lawrence Wong; Robert M Califf; Keith A A Fox; Werner Hacke
Journal:  Lancet Neurol       Date:  2012-03-07       Impact factor: 44.182

Review 3.  Aging biology and geriatric clinical pharmacology.

Authors:  Allan J McLean; David G Le Couteur
Journal:  Pharmacol Rev       Date:  2004-06       Impact factor: 25.468

4.  Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.

Authors:  Amitava Banerjee; Deirdre A Lane; Christian Torp-Pedersen; Gregory Y H Lip
Journal:  Thromb Haemost       Date:  2011-12-21       Impact factor: 5.249

Review 5.  Review: the frequency and severity of adverse drug reactions in elderly people.

Authors:  J Walker; H Wynne
Journal:  Age Ageing       Date:  1994-05       Impact factor: 10.668

6.  High-risk prescribing and incidence of frailty among older community-dwelling men.

Authors:  D Gnjidic; S N Hilmer; F M Blyth; V Naganathan; R G Cumming; D J Handelsman; A J McLachlan; D R Abernethy; E Banks; D G Le Couteur
Journal:  Clin Pharmacol Ther       Date:  2012-02-01       Impact factor: 6.875

Review 7.  Drug therapy in the elderly.

Authors:  Rudolf E Noble
Journal:  Metabolism       Date:  2003-10       Impact factor: 8.694

8.  Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study.

Authors:  H Buller; D Deitchman; M Prins; A Segers
Journal:  J Thromb Haemost       Date:  2008-06-06       Impact factor: 5.824

9.  Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.

Authors:  Wolfgang Mueck; Bengt I Eriksson; Kenneth A Bauer; Lars Borris; Ola E Dahl; William D Fisher; Michael Gent; Sylvia Haas; Menno V Huisman; Ajay K Kakkar; Peter Kälebo; Louis M Kwong; Frank Misselwitz; Alexander G G Turpie
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

10.  The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.

Authors:  M R Lassen; B L Davidson; A Gallus; G Pineo; J Ansell; D Deitchman
Journal:  J Thromb Haemost       Date:  2007-09-15       Impact factor: 5.824

View more
  1 in total

1.  Urgent monitoring of direct oral anticoagulants in patients with atrial fibrillation: a tentative approach based on routine laboratory tests.

Authors:  Giuseppe Lippi; Diego Ardissino; Roberto Quintavalla; Gianfranco Cervellin
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.